The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer

The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)‐guided precision treatment in metastatic castration‐resistant prostate cancer (mCRPC). The objective of this study was to evaluate the prevalence and prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jian, Zhao, Jinou, Ni, Xudong, Gan, Hualei, Wei, Yu, Wu, Junlong, Zhang, Tingwei, Wang, Qifeng, Freedland, Stephen J., Wang, Beihe, Song, Shaoli, Ye, Dingwei, Liu, Chang, Zhu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718110/
https://www.ncbi.nlm.nih.gov/pubmed/36209367
http://dx.doi.org/10.1002/1878-0261.13320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718110/
https://www.ncbi.nlm.nih.gov/pubmed/36209367
http://dx.doi.org/10.1002/1878-0261.13320

Ejemplares similares